Skip to content

Study · Case report or series · n = 1 · 2025

6 results

Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature.

Zhang Y, Li A

Open medicine (Warsaw, Poland)23 Apr 2025

PMID40292250 (opens in a new tab)PMCIDPMC12032985 (opens in a new tab)DOI10.1515/med-2025-1184 (opens in a new tab)PepBankPUB-40292250
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundComorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.MethodsWe describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy. She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin. Clinical, biochemical, and molecular parameters were monitored.ResultsAfter 6 months, her HbA1c declined from 10.7 to 5.5%, fasting plasma glucose from 16.2 to 5.3 mmol/L, and body weight decreased by 18 kg. Lipid parameters improved, and molecular analysis confirmed continued CML remission (undetectable BCR-ABL1). The patient experienced only mild, transient gastrointestinal side effects.ConclusionIn this complex case, semaglutide proved safe and effective for achieving glycemic control and weight reduction without compromising CML stability. These findings suggest that GLP-1 receptor agonists may be a viable therapeutic option for patients with coexisting T2DM, severe obesity, and stable CML, warranting further investigation in broader populations.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 33-year-old woman with type 2 diabetes, severe obesity and stable CML, HbA1c fell from 10.7% to 5.5% over 6 months of once-weekly semaglutide given alongside insulin glargine and dapagliflozin/metformin.

    In plain wordsIn one woman with type 2 diabetes, severe obesity and stable CML, HbA1c fell from 10.7% to 5.5% over 6 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5-1.5 mg once weekly · 6 monthsAs given in this study (human).

    Measurements

    HbA1c
    10.7%
    baseline
    HbA1c
    5.5%
    6 months

    Source sentences

    Summary
    After 6 months, her HbA1c declined from 10.7 to 5.5%
    2 context sentences
    Summary · context
    We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy.
    Summary · context
    She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin.
  2. 02HumanCase report or seriesEfficacy outcome

    In the same patient, fasting plasma glucose fell from 16.2 to 5.3 mmol/L over 6 months of once-weekly semaglutide given alongside insulin glargine and dapagliflozin/metformin.

    In plain wordsIn this woman, fasting blood glucose fell from 16.2 to 5.3 mmol/L over 6 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5-1.5 mg once weekly · 6 monthsAs given in this study (human).

    Measurements

    Fasting plasma glucose
    16.2 mmol/L
    baseline
    Fasting plasma glucose
    5.3 mmol/L
    6 months

    Source sentences

    Summary
    fasting plasma glucose from 16.2 to 5.3 mmol/L
    2 context sentences
    Summary · context
    We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy.
    Summary · context
    She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin.
  3. 03HumanCase report or seriesEfficacy outcome

    In the same patient, body weight decreased by 18 kg over 6 months of once-weekly semaglutide given alongside insulin glargine and dapagliflozin/metformin.

    In plain wordsIn this woman, body weight fell by 18 kg over 6 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5-1.5 mg once weekly · 6 monthsAs given in this study (human).

    Measurements

    Body weight change
    −18 kg
    6 months

    Source sentences

    Summary
    body weight decreased by 18 kg
    2 context sentences
    Summary · context
    We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy.
    Summary · context
    She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin.
  4. 04HumanCase report or seriesEfficacy outcome

    In the same patient, lipid parameters improved during once-weekly semaglutide treatment; no values were given.

    In plain wordsIn this woman, blood fat levels improved while taking semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedLipid parameters
    Study

    n = 1

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.5-1.5 mg once weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Lipid parameters improved, and molecular analysis confirmed continued CML remission (undetectable BCR-ABL1).
    2 context sentences
    Summary · context
    We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy.
    Summary · context
    She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin.
  5. 05HumanCase report or seriesSafety outcome

    In the same patient, molecular analysis confirmed continued CML remission (undetectable BCR-ABL1) during once-weekly semaglutide treatment.

    In plain wordsIn this woman, her leukemia stayed in remission while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeCML remission (BCR-ABL1)
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    0.5-1.5 mg once weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Lipid parameters improved, and molecular analysis confirmed continued CML remission (undetectable BCR-ABL1).
    2 context sentences
    Summary · context
    We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy.
    Summary · context
    She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin.
  6. 06HumanCase report or seriesSafety outcome

    In the same patient, only mild, transient gastrointestinal side effects were reported during once-weekly semaglutide treatment.

    In plain wordsIn this woman, only mild gut side effects that did not last were reported while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal side effects
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.5-1.5 mg once weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient experienced only mild, transient gastrointestinal side effects.
    2 context sentences
    Summary · context
    We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy.
    Summary · context
    She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.